Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant anti-TNF-α mAb vs Humira in rheumatoid arthritis
CTR20170415Phase 3Completed
- Sponsor
- Jiangsu Zhonghe Pharmaceutical Technology
- Start
- May 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of adalimumab in rheumatoid arthritis (RA), sponsored by Jiangsu Zhonghe Pharmaceutical Technology. Started May 2017; status: completed.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on CTR20170415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20170415.